Literature DB >> 2415239

Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody.

R K Chiou, R L Vessella, M K Elson, R V Clayman, J M Gonzalez-Campoy, M J Klicka, R B Shafer, P H Lange.   

Abstract

We previously described an immunoglobulin G1 monoclonal antibody (UMVA-RCC-A6H) that is highly reactive with human renal cell carcinoma (RCC) and has little cross-reactivity to other cell types both normal and malignant. In efforts detailed herein, radiolabeled A6H selectively localized to RCC xenografts and provided high resolution images of the xenografts. Also, A6H clearly discriminated between RCC xenografts and other human tumor xenografts. Consistent images of RCC xenografts (greater than 60 mg) were obtained without background subtraction. The amount of radiolabeled A6H in the tumor usually ranged from five to twenty times that of the blood. Normal mouse tissues, abscesses, and other human tumor xenografts contained less radiolabel per mg than did blood. A control monoclonal antibody of the same isotype failed to exhibit any localization in xenografts or normal tissues. Approximately 40% of the radiolabeled A6H dose per g was localized in the RCC xenograft 2 days after injection, although at the time of imaging about 60% of the radiolabel remaining in the mouse was associated with the xenograft. These results demonstrate that a RCC restrictive monoclonal antibody does specifically localize to RCC xenografts and supports the hope that this approach may have clinical value for diagnosis, staging, or treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415239

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

2.  Echinococcus granulosus: the potential use of specific radiolabelled antibodies in diagnosis by immunoscintigraphy.

Authors:  M T Rogan; D L Morris; D I Pritchard; A C Perkins
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

3.  Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.

Authors:  E Oosterwijk; F M Debruyne
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 4.  Radiolabeled antibodies in renal cell carcinoma.

Authors:  Alexander B Stillebroer; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders; Otto C Boerman
Journal:  Cancer Imaging       Date:  2007-11-19       Impact factor: 3.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.